The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.
In the formula, n is 1 or 2; R
A
is a hydrogen atom or a hydroxyl group; R
1
is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R
2
to R
4
, P
1
and Q represents a halogen atom, a cyano group or the like.
本发明提供了一种8-修饰
嘌呤核苷衍
生物,用于与血浆
尿酸水平异常相关的疾病。公式(I)所表示的8-修饰
嘌呤核苷衍
生物,其前体药物或其药学上可接受的盐,或其
水合物或溶剂化物,可用于痛风、高
尿酸血症、泌尿系结石、高
尿酸性肾病等的预防或治疗。在公式中,n为1或2;RA是氢原子或羟基;R1是氢原子、羟基、
硫醇基、
氨基或
氯原子;环J表示可选取的2-
萘基团,或由以下通式(II)所表示的基团,其中Y表示单键或连接基团;环Z表示可选取的芳基团或杂环芳基团等;R2到R4、P1和Q表示卤素原子、
氰基或类似物。